How to Manage Medication After Returning from IVF Abroad: Transition Plan & Precautions

Opening: Real Consultation Scenario

▎Consultation Scenario
On the 4th day after embryo transfer in Thailand, Ms. Lin returned to China with only 6 Crinone suppositories left and enough dydrogesterone for just 5 days. She took her Thai prescription to a local tertiary hospital, only to be told the exact imported drugs were unavailable. The doctor suggested switching to a domestic progesterone injection, but she was unsure about the dosage and administration. This is the most common medication transition issue faced by overseas IVF patients returning home.

Module I: Practical Process

Standard Process for Medication Transition After Returning Home

Regardless of which country you return from, the core logic of medication transition is: Maintain effective serum drug concentration without interrupting luteal phase support. The standard process includes the following four steps:

1. Confirm Medication List Before Discharge: Request a detailed medication plan from the overseas fertility center, including drug name, dosage, administration route, and expected duration. Ask for an English or Chinese version, and ensure the INN (International Nonproprietary Name) is indicated.
2. Estimate Medication Gap: Based on your return date and medication schedule, calculate how long your current supply will last. If the gap exceeds 3 days, arrange domestic access in advance.
3. Establish Follow-up Records Domestically: Within 48 hours of returning, visit the "Reproductive Endocrinology" or "Assisted Reproduction Follow-up" clinic at a tertiary hospital with a fertility center. Bring your overseas medical summary, medication plan, and transfer records.
4. First Monitoring Milestone: Complete your first blood test on day 3-5 after returning, including progesterone (P), estradiol (E2), and hCG (if close to the pregnancy test date). Adjust medication based on results thereafter.

Module A: Direct Answers

Direct Solutions for Medication Transition

Regarding "How to manage medication after returning from IVF abroad," here are corresponding plans based on transfer type:

Transfer Type	Medication Plan Characteristics	Domestic Transition Method
Fresh Cycle Transfer	Luteal support primarily with progestins, sometimes combined with hCG or GnRH agonists	Progesterone can be replaced with domestic formulations of the same component; hCG requires doctor's adjustment
Natural Cycle FET	Only progesterone supplementation needed; relatively simple regimen	Dydrogesterone or vaginal progesterone can be continued directly; monitor ovulation to confirm endometrial transformation
Artificial Cycle FET	Combined estradiol + progesterone support; longer medication duration	Estradiol can be replaced with Progynova or Femoston; convert progesterone according to original plan
Down-regulated Cycle FET	GnRH agonist + estradiol + progesterone; complex protocol	Requires domestic reproductive doctor evaluation to continue down-regulation; do not stop medication on your own

Key Principle Do not stop medication on your own, do not change dosage arbitrarily, and do not switch drugs without monitoring. Any medication conversion should be done under a doctor's guidance, choosing formulations with similar bioavailability whenever possible.

Module G: Most Overlooked Details

Five Most Overlooked Details

• Same Drug Name but Different Concentration: For example, Crinone 8% gel and some domestic progesterone sustained-release gels may have different concentration labeling. Check the milligrams of active ingredient per unit.
• Route of Administration Affects Serum Concentration: Overseas, vaginal sustained-release gels are common; domestic hospitals often use intramuscular injections. Monitor serum concentration during conversion to avoid insufficient luteal support due to absorption differences.
• Differences in Progesterone Normal Range: Reference ranges for progesterone vary between laboratories and kits. When monitoring domestically, use the local laboratory's reference range and compare with overseas reports for conversion.
• Customs Medication Limits: When bringing prescription drugs from overseas for personal use, a reasonable quantity typically does not exceed a 3-month supply. Some drugs contain hormones; keep the original prescription and purchase receipts.
• Cold Chain Disruption: Vaginal suppositories like Crinone and Utrogestan must be stored below 25°C. During long flights, exposure to high temperatures may reduce efficacy. Check the gel consistency; stop using if separation or discoloration occurs.

Module H: Common Pitfalls

Three Most Common Pitfalls

Module C: Doctor's Perspective

Core Advice from Reproductive Doctors on Medication Transition

From a clinical perspective, the two biggest concerns in medication transition are treatment interruption and dosage errors. As a reproductive doctor, I advise patients to treat medication transition after returning home as a "medical transfer":

• Establish Two-way Communication: Before discharge, ask your overseas doctor to write a brief medication instruction letter, including drug name, dosage, start and end dates, and "acceptable alternatives if the same drug is unavailable domestically."
• Prioritize Hospitals with Fertility Centers: Fertility centers in tertiary hospitals have more experience with medication transitions for overseas IVF patients. Doctors there are familiar with different countries' medication practices and can make reasonable adjustments quickly.
• Don't Wait Until You're Almost Out of Medication: Obtaining drugs, scheduling hospital visits, and arranging tests take time. Start the transition process when you have about 7 days of medication left.

Additionally, progesterone monitoring should not be done just once. During luteal support, progesterone levels fluctuate physiologically. A single low reading doesn't necessarily indicate a problem; it must be interpreted in the context of medication timing, administration route, and clinical symptoms.

Module E: Differences Between Countries

Differences in Medication Plans Across Countries and Transition Key Points

Country/Region	Common Luteal Support Drugs	Domestic Transition Considerations
Thailand	Crinone, Dydrogesterone, Utrogestan, hCG	Crinone same specification as domestic; Dydrogesterone can be continued directly
United States	Crinone, Oral Progesterone (Prometrium), Progesterone Injection (PIO)	Check oral progesterone dosage (mg vs mcg); PIO has equivalent oil-based injection domestically
Japan	Progesterone Injection (Progesterone), Oral Progesterone (Lutoral), Vaginal Suppositories	Injectable progesterone concentration differs from domestic; recalculate single dose
Malaysia	Crinone, Dydrogesterone, Estradiol (Estrace), GnRH agonists	Estrace can be replaced with equivalent Progynova; agonists need doctor confirmation of brand

Tip Regardless of which country you return from, keep original packaging and instructions to help domestic doctors quickly identify ingredients and dosages.

Module N: Special Situations

Handling Special Situations

Situation 1: Drug Completely Unavailable
If the exact overseas drug is not available domestically (e.g., certain combination products), a domestic doctor will follow the equivalent dose principle to switch to a similar drug. For example, if an overseas oral progesterone capsule is unavailable, it can be replaced with dydrogesterone or vaginal progesterone gel, with appropriate single-dose adjustment.

Situation 2: Allergy or Adverse Reaction After Medication
If you had no adverse reactions during overseas treatment but develop a rash, dizziness, or local irritation after switching to a domestic brand, stop the medication immediately and consult a doctor. The doctor will assess whether it's due to the active ingredient or excipient differences and switch to another formulation.

Situation 3: Missed Pregnancy Test or Monitoring Time
If you miss the scheduled pregnancy test due to time zone changes or scheduling issues, take the hCG test as soon as possible while continuing luteal support. Do not interrupt medication while waiting for results.

Situation 4: Need for Extended Luteal Support
Some patients with low progesterone levels or recurrent implantation failure may be advised to extend luteal support beyond 12 weeks of pregnancy. Discuss with your domestic doctor to create a continuation plan, often involving gradual dose reduction or switching to oral formulations.

Module Q: Frequently Asked Questions

Frequently Asked Questions

Knowledge Graph Entity Natural Coverage Closing: Risk Reminder Doctor Signature

Reproductive Doctor · Patient Education Column